- Home
- DHF vs OABI Comparison
DHF vs OABI Comparison
Compare DHF & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- OABI
- Stock Information
- Founded
- DHF 1998
- OABI 2012
- Country
- DHF United States
- OABI United States
- Employees
- DHF N/A
- OABI N/A
- Industry
- DHF Finance Companies
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- OABI Health Care
- Exchange
- DHF Nasdaq
- OABI Nasdaq
- Market Cap
- DHF 172.4M
- OABI 198.2M
- IPO Year
- DHF N/A
- OABI N/A
- Fundamental
- Price
- DHF $2.60
- OABI $1.93
- Analyst Decision
- DHF
- OABI Strong Buy
- Analyst Count
- DHF 0
- OABI 3
- Target Price
- DHF N/A
- OABI $7.00
- AVG Volume (30 Days)
- DHF 451.1K
- OABI 912.8K
- Earning Date
- DHF 01-01-0001
- OABI 08-07-2025
- Dividend Yield
- DHF 7.65%
- OABI N/A
- EPS Growth
- DHF N/A
- OABI N/A
- EPS
- DHF N/A
- OABI N/A
- Revenue
- DHF N/A
- OABI $26,744,000.00
- Revenue This Year
- DHF N/A
- OABI N/A
- Revenue Next Year
- DHF N/A
- OABI $45.65
- P/E Ratio
- DHF N/A
- OABI N/A
- Revenue Growth
- DHF N/A
- OABI 27.07
- 52 Week Low
- DHF $2.06
- OABI $1.22
- 52 Week High
- DHF $2.39
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- DHF 67.13
- OABI 69.01
- Support Level
- DHF $2.50
- OABI $1.55
- Resistance Level
- DHF $2.61
- OABI $1.73
- Average True Range (ATR)
- DHF 0.03
- OABI 0.10
- MACD
- DHF 0.01
- OABI 0.03
- Stochastic Oscillator
- DHF 90.91
- OABI 100.00
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.